Douglas F. Beach, MD
Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
Penn Medicine Provider

About me

  • Director, CREP/Breast and Ovarian Cancer Program
  • Associate Program Director, Internal Medicine Residency
  • Clinical Associate Professor of Medicine (Hematology-Oncology)

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: Cooper University Hospital
  • Fellowship: Cooper University Hospital

What my patients think about me

Average Rating

872 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
clean and friendly
November 2025
i have recommended.
November 2025
exceptional care.
October 2025
he is a great physician

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Beach is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study , Blood (2020) 136 (Supplement 1): 37–39, 136: 2020,37–39


Riley SV, Beach DF. Making Progress: Impact of Diabetes on Metastatic Colon Cancer Disease Progression. , J. Neoplasm. , 5(1:1): 2020


Mato, A. R., Roeker, L. E., Allan, J. N., Pagel, J. M., Brander, D. M., Hill, B. T., Cheson, B. D., Furman, R. R., Lamanna, N., Tam, C. S., Handunnetti, S., Jacobs, R., Lansigan, F., Bhavsar, E., Barr, P. M., Shadman, M., Skarbnik, A. P., Goy, A., Beach, D. F., Svoboda, J., Pu, J. J., Sehgal, A. R., Zent, C. S., Tuncer, H. H., Schuster, S. J., Pickens, P. V., Shah, N. N., Rhodes, J., Ujjani, C. S., Nabhan, C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. , Am J Hematol, 93(11): 2018,1394-1401


Danielle M. Brander, MD, Joanna Rhodes, MD, John M. Pagel, MD PhD, Chadi Nabhan, MD MBA, FACP, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Ryan Jacobs, MD, Brian T. Hill, MD PhD, Nicole Lamanna, MD, Frederick Lansigan, MD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Alan P Skarbnik, MD, Bruce D. Cheson, MD, Jeffrey J. Pu, MD PhD, Alison R. Sehgal, MD, Paul M. Barr, MD, John N. Allan, MD, Douglas F. Beach, MD, Bhavisha Patel, MD, Peter V. Pickens, MD, Sunita Dwivedy Nasta, MD, Kaitlin Kennard, RN, BSN, Hande H. Tuncer, MD, Brittany Koch, MPH, Richard R. Furman, MD, Anthony R. Mato, MD Applicability of the Chronic Lymphocytic Leukemia (CLL)-IPI on Patients Treated with Front-Line Ibrutinib in the Real World: The Case for New Prognostic Models , Blood, 130 (Supplement 1): 2017


Anthony R. Mato, MD, John N. Allan, MD, John M. Pagel, MD PhD, Danielle M. Brander, MD, Brian T. Hill, MD PhD, Bruce D. Cheson, MD, Richard R. Furman, MD, Nicole Lamanna, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Ryan Jacobs, MD, Frederick Lansigan, MD, Paul M. Barr, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Douglas F. Beach, MD, Jeffrey J. Pu, MD PhD, Alison R. Sehgal, MD, Allison M. Winter, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Arun K Singavi, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Annalynn Williams, MS, Christina Howlett, PharmD, BCOP, Hanna Weissbrot, BS, Naveed Ali, MD, Bhavisha Patel, MD, Krista Isaac, DO, MS, Joanna Rhodes, MD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Sirin Khajavian, MD, Elizabeth T Chatburn, BS, Andrea Sitlinger, MD, Eve Tranchito, BS, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Kaitlin Kennard, RN, BSN, Chadi Nabhan, MD MBA, FACP, Chaitra S. Ujjani, MD Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies , Blood, 130 (Supplement 1): 2017


Oren O, Oren M, Beach D On the generalizability of prostate cancer studies: why race matters. , Ann Oncol , 27(12): 2016,2146-2148


Grant S, Meykler S, Beach D Superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma. , J Community Support Oncol , 12(11): 2014,415-417


Beach DF, Barnoski B, Patel V, Schwarting R, Strair R, Lachant N Duplication of chromosome 1 [dup(1)(q21q32)] as the sole cytogenetic abnormality in a patient previously treated for AML. , Cancer Genetics, 205(12): 2012,665-668


Beach DF, Klump W, Haddad G, Reid LM, Schwarting R, Hageboutros A. Extrapulmonary small cell: a novel case of small cell carcinoma of the thyroid gland. , Medical Oncology, 29(3): 2012,1405-1408


Beach D, Somer R Metastatic Renal Cell Carcinoma to the Phalanx. , Urology, 79(5): 2012,e77